JAMA Netw Open:糖尿病患者想要更好的管理体重和血糖,那就试试智能手机应用程序吧

2021-06-14 MedSci原创 MedSci原创

生活方式干预在糖尿病管理中是有效的,管理健康数据和饮食及运动计划的智能手机应用程序越来越受欢迎。然而,有关基于智能手机干预措施在亚洲成人2型糖尿病患者中的有效性证据有限。

生活方式干预在糖尿病管理中是有效的,管理健康数据和饮食及运动计划的智能手机应用程序越来越受欢迎。然而,有关基于智能手机干预措施在亚洲成人2型糖尿病患者中的有效性证据有限。

pixabay

近日,发表在JAMA Netw Open杂志的一项研究显示,与常规护理相比,基于智能手机的生活方式干预在降低亚洲 2 型糖尿病成人的体重和血糖方面更有效,支持在生活方式干预中使用应用程序。

在这项研究中,研究人员对来自新加坡多个初级保健中心进行的 305 名患有 2 型糖尿病且体重指数 (BMI) 23 或更高的成年人进行试验,这些参与者均具有良好的英语读写能力和使用智能手机的能力。最终纳入204 名符合要求的参与者,并随机分配干预组(n=99)或对照组(n=105)。

试验设计

同时,对照组和干预组的参与者均接受了营养师的饮食和身体活动建议,干预组还使用一个智能手机应用程序来跟踪其体重、饮食、体育活动和血糖,平均随访6个月。最终主要结局为体重的变化,而次要结果是血红蛋白A1cHbA1c)、空腹血糖、血压、血脂和饮食的变化。

结果显示,在204名参与者中,平均年龄为51.2岁,64.7%为男性,基线平均BMI30.6。与对照组相比,干预组体重和HbA1c水平明显下降,干预组参与者体重平均减少3.6公斤,HbA1水平平均变化为0.7%。同时,6个月时,干预组有更多的人减少了糖尿病药物治疗。

 3 个月和 6 个月的主要和次要结果

HbA1c水平为8%或更高的参与者中,干预措施使得HbA1c水平有个更大幅度的降低(平均[SD]变化,-1.8%[1.4] vs -1.0%[1.4]P = .001)。在空腹血糖、舒张压和饮食变化方面,干预组和对照组有着明显的差异。

综上,尽管减少了面对面的互动,但本研究中应用程序的使用在糖尿病患者全程管理中取得了相似的干预效果。基于智能手机的生活方式干预能够在未接受胰岛素治疗的 2 型糖尿病和超重或肥胖的亚洲成年人中实现有意义的体重减轻。此外,应用程序干预显著改善了血糖,尤其是在糖尿病控制不佳的个体中,同时减少了糖尿病药物使用。

原始出处

Su Lin Lim, PhD1Kai Wen Ong, BSc1Jolyn Johal, BSc2et al.Effect of a Smartphone App on Weight Change and Metabolic Outcomes in Asian Adults With Type 2 Diabetes A Randomized Clinical Trial.JAMA Netw Open. 2021;4(6):e2112417. doi:10.1001/jamanetworkopen.2021.12417

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-09-20 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-10-01 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-26 任我行3313

    所以科技改变生活

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-15 1881ef655dm

    学习啦

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-15 148bedacm12暂无昵称

    学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-14 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-14 misszhang

    谢谢MedSci提供最新的资讯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1734375, encodeId=2f371e3437572, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Sep 20 23:05:13 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085417, encodeId=1c9d208541e9f, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jul 08 16:05:13 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728975, encodeId=6fe61e2897546, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Oct 01 16:05:13 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977147, encodeId=e4359e71474e, content=所以科技改变生活, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oywRKRLSzibJMv3JHUmUVJQ&s=100&t=1557394800, createdBy=81e05325887, createdName=任我行3313, createdTime=Sat Jun 26 22:14:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475086, encodeId=10d114e508622, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 16 07:05:13 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973808, encodeId=a5a49e380847, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Tue Jun 15 18:00:15 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973633, encodeId=cc1b9e36336b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=148bedacm12暂无昵称, createdTime=Tue Jun 15 07:32:16 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036677, encodeId=a73a10366e740, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043649, encodeId=88a110436491d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jun 14 19:05:13 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973479, encodeId=46bc9e34793d, content=写的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e635479749, createdName=ms2000002016659512, createdTime=Mon Jun 14 16:27:00 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-14 ms2000002016659512

    写的好

    0

相关资讯

纪立农:做糖尿病管理 首先应考虑如何降低早死率

全球流行病学的数据显示,由主要慢性非传染性疾病(肿瘤、心血管疾病、糖尿病和慢性呼吸系统疾病)导致的过早死亡(定义为30岁~70岁间死亡),占人类过早死亡的80%左右。减少这些疾病所导致的过早死亡是提高人群预期寿命的主要途径。那么我们目前面临着怎样的慢病管理的现状以及如何更好地进行慢病管理?本期,特邀北京大学糖尿病中心、北京大学人民医院内分泌科主任纪立农为我们介绍如何通过慢病管理来助力实现健康中国的

Diabetes care:强化治疗可减少1型糖尿病患者长期并发症

研究要点: DCCT/EDIC研究探讨强化治疗是否可以预防或延缓1型糖尿病患者长期并发症;发现强化治疗可降低1型糖尿病患者长期并发症,并能改善患者预期健康寿命。 糖尿病控制与并发症研究(DCCT)旨在验证“血糖假说“,并确定1型糖尿病(T1DM)并发症是否可以被预防或延缓。DCCT后继的观察性糖尿病干预及并发症的流行病学(EDIC)研究进一步确定DCCT研究的持久性,对更严重糖尿病

Diabetes Care:有效的服药依从性自我报告利于2型糖尿病管理

  来自美国的一项研究结果,支持易于管理的自我报告对改善糖尿病患者服药依从性的有效性。在1个月内,按百分比计算评级的服药依从性,与药物事件监视系统(MEMS)和糖化血红蛋白之(HbA1c)间显示最强的关联;而在那些需要报告错误剂量的受试者中,有较弱的关联。为期一周、要求受访者记录错误剂量数量的自我评价和测量,表现为易于受到抑郁症严重程度的影响而产生偏差。研究在2012年11月30日在线发表于《糖尿

探索“互联网+医联体”糖尿病管理新路径——中西医结合代谢性疾病(糖尿病)标准化管理项目在京启动

2020年12月10日,北京中医药大学糖尿病研究中心牵头发起的中西医结合代谢性疾病(糖尿病)标准化管理项目在京正式启动,标志着“互联网+医联体”模式下中西医结合糖尿病标准化管理进入全新的发展阶段,是践

Nat Commun:合成基因回路或助人轻松管理糖尿病

英国《自然·通讯》杂志 19 日 发表 一项合成生物学新进展:欧洲科学家团队设计出了一种全新合成生物学基因回路,并证明可以通过咖啡因激活这种合成基因回路。小鼠糖尿病模型研究显示,其可以成功调节血糖水平。该研究成果或将助力人类对抗糖尿病,同时亦展示了合成生物学在医疗界的应用潜力。

Diabetic Medicine:随着时间的推移,1型糖尿病患者的糖尿病困扰与糖尿病管理恶化有关

近日,国际杂志 《Diabetic Medicine》上在线发表一项根据德国健康保险数据进行分析的研究,发现关于尽管有新的药物,2型糖尿病患者严重低血糖发生率有所增加。通过分析比较2006年和2011年与药物相关的严重低血糖发生率,评估提供有效血糖控制同时降低低血糖风险的新抗高血糖药物的使用。